Gene Therapy for Spinal Muscular Atrophy Effective as First- or Second-line Therapy

Head-to-Head Trial Shows Large Clinical Advantage for CGRP Monoclonal Antibody in Migraine Prophylaxis

New Data from Head-to-head and Long-term Follow-up BTK Inhibitor Trials Clarify Choices in CLL

SELECT-PsA 1 and SELECT-PsA 2 Extended Trial Results Show Persistent Efficacy in Psoriatic Arthritis

Efficacy of Spinal Muscular Atrophy Therapies Depends on Early Initiation

ETNA-AF Registry: All Atrial Fibrillation Subgroups, Even the Old and Frail, Are Included in NOAC Benefit

New Data Emphasize Prompt Initiation of ARNI Therapy as a Standard of Care for HFrEF in Patients With and Without Diabetes

Spinal Muscular Atrophy Remains Controlled in a Phase 3 Study with New Gene Therapy: SPR1NT Trial

Cognitive Function as an Endpoint in Secondary Progressive Multiple Sclerosis

Long-term Control of Rheumatoid Arthritis: Oral Targeted Agent Shows Sustained Advantage Over Biologic

SELECT-PsA 1 & SELECT-PsA 2: Oral Targeted Therapy for PsA Promises Efficacy in Bio-Naïve and Refractory Patients

Control of Pathology Beyond the Skin Might Best Characterize Benefit of Psoriasis Therapy